AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oramed Pharmaceuticals Inc. Director's Dealing 2024

Jan 8, 2024

6965_dirs_2024-01-08_54634adb-4d0f-4d88-8f03-f9f9b0a62f2c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2024-01-04

Reporting Person: Rozov Yadin (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-04	Common Stock	A	30000	—	Acquired	146500	Direct
2024-01-04	Common Stock	A	8820	—	Acquired	155320	Direct

Footnotes

F1: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2025, January 1, 2026 and January 1, 2027. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

F2: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of 2,205 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.